PMC:7696151 / 71780-72048 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2089","span":{"begin":109,"end":113},"obj":"Species"},{"id":"2094","span":{"begin":45,"end":48},"obj":"Chemical"},{"id":"2095","span":{"begin":183,"end":192},"obj":"Chemical"},{"id":"2106","span":{"begin":62,"end":89},"obj":"Disease"},{"id":"2107","span":{"begin":100,"end":108},"obj":"Disease"},{"id":"2108","span":{"begin":229,"end":247},"obj":"Disease"}],"attributes":[{"id":"A2089","pred":"tao:has_database_id","subj":"2089","obj":"Tax:10090"},{"id":"A2094","pred":"tao:has_database_id","subj":"2094","obj":"MESH:D006886"},{"id":"A2095","pred":"tao:has_database_id","subj":"2095","obj":"MESH:D000068581"},{"id":"A2106","pred":"tao:has_database_id","subj":"2106","obj":"MESH:D015427"},{"id":"A2107","pred":"tao:has_database_id","subj":"2107","obj":"MESH:D003920"},{"id":"A2108","pred":"tao:has_database_id","subj":"2108","obj":"MESH:D009203"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ts of one week of treatment with 50 mg/kg of HCQ i.g. against ischemia-reperfusion injury in type-2 diabetic mice were assessed in combination with the phosphodiesterase-5 inhibitor, tadalafil. The synergistic effect reduced the myocardial infarct size by up to 20% an"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T132","span":{"begin":229,"end":247},"obj":"Phenotype"}],"attributes":[{"id":"A132","pred":"hp_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/HP_0001658"}],"text":"ts of one week of treatment with 50 mg/kg of HCQ i.g. against ischemia-reperfusion injury in type-2 diabetic mice were assessed in combination with the phosphodiesterase-5 inhibitor, tadalafil. The synergistic effect reduced the myocardial infarct size by up to 20% an"}